Advancis Gets “Refuse To File” Letter For Pulsatile Amoxicillin NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm may need to manufacture commercial-sized quantities of antibiotic in order for FDA to accept the submission.